|
|
 Previous Article | Table of Contents | Next Article 
Myelodysplastic Syndrome and Acute Myelogenous Leukemia as a Late Clonal Complication in Children With Acquired Aplastic Anemia
Akira Ohara,
Seiji Kojima,
Nobuyuki Hamajima,
Masahiro Tsuchida,
Shinsaku Imashuku,
Shigeru Ohta,
Hideki Sasaki,
Jun Okamura,
Kanji Sugita,
Hisato Kigasawa,
Yukio Kiriyama,
Junichi Akatsuka, and
Ichiro Tsukimoto
From the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology.
The improved outcome of acquired aplastic anemia (AA) has revealed later complications, such as myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). We retrospectively analyzed 167 children with severe acquired AA. Eleven of 50 children treated with cyclosporin (CSA) and recombinant human granulocyte colony-stimulating factor (rhG-CSF ) developed MDS/AML; 8 of these were within 36 months of the diagnosis of AA, much earlier than previous reports. Six of the 11 children received rhG-CSF exceeding 10 µg/kg/d, and 9 received rhG-CSF therapy for over 1 year. Ten children showed monosomy 7 at diagnosis of MDS. All of the 11 children were administered both CSA and rhG-CSF. There was no development of MDS/AML among 41 children treated with either CSA or rhG-CSF or among 48 children who underwent bone marrow transplantation. A well-controlled clinical trial is warranted to determine whether therapeutic modalities affect the development of MDS/AML in children with severe acquired AA.
Blood, Vol. 90 No. 3 (August 1), 1997:
pp. 1009-1013
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. Gurion, A. Gafter-Gvili, M. Paul, L. Vidal, I. Ben-Bassat, M. Yeshurun, O. Shpilberg, and P. Raanani
Hematopoietic growth factors in aplastic anemia patients treated with immunosuppressive therapy-systematic review and meta-analysis
Haematologica,
May 1, 2009;
94(5):
712 - 719.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kosaka, H. Yagasaki, K. Sano, R. Kobayashi, H. Ayukawa, T. Kaneko, H. Yabe, M. Tsuchida, H. Mugishima, A. Ohara, et al.
Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia
Blood,
February 1, 2008;
111(3):
1054 - 1059.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. P. Alter and P. S. Rosenberg
Granulocyte colony-stimulating factor and severe aplastic anemia
Blood,
May 15, 2007;
109(10):
4589 - 4589.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Socie, J.-Y. Mary, H. Schrezenmeier, J. Marsh, A. Bacigalupo, A. Locasciulli, M. Fuehrer, A. Bekassy, A. Tichelli, and J. Passweg
Granulocyte-stimulating factor and severe aplastic anemia: a survey by the European Group for Blood and Marrow Transplantation (EBMT)
Blood,
April 1, 2007;
109(7):
2794 - 2796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bacigalupo
Aplastic Anemia: Pathogenesis and Treatment
Hematology,
January 1, 2007;
2007(1):
23 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Maciejewski, E. M. Sloand, O. Nunez, C. Boss, and N. S. Young
Recombinant humanized anti-IL-2 receptor antibody (daclizumab) produces responses in patients with moderate aplastic anemia
Blood,
November 15, 2003;
102(10):
3584 - 3586.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V. Relling, J. M. Boyett, J. G. Blanco, S. Raimondi, F. G. Behm, J. T. Sandlund, G. K. Rivera, L. E. Kun, W. E. Evans, and C.-H. Pui
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment
Blood,
May 15, 2003;
101(10):
3862 - 3867.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Frickhofen, H. Heimpel, J. P. Kaltwasser, and H. Schrezenmeier
Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia
Blood,
February 15, 2003;
101(4):
1236 - 1242.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Wang, T. Chuhjo, S. Yasue, M. Omine, and S. Nakao
Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome
Blood,
December 1, 2002;
100(12):
3897 - 3902.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kojima, A. Ohara, M. Tsuchida, T. Kudoh, R. Hanada, Y. Okimoto, T. Kaneko, T. Takano, K. Ikuta, and I. Tsukimoto
Risk factors for evolution of acquired aplastic anemia into myelodysplastic syndrome and acute myeloid leukemia after immunosuppressive therapy in children
Blood,
July 18, 2002;
100(3):
786 - 790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Maciejewski, A. Risitano, E. M. Sloand, O. Nunez, and N. S. Young
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia
Blood,
May 1, 2002;
99(9):
3129 - 3135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Brodsky, L. L. Sensenbrenner, B. D. Smith, D. Dorr, P. J. Seaman, S. M. Lee, J. E. Karp, I. Brodsky, and R. J. Jones
Durable Treatment-Free Remission after High-Dose Cyclophosphamide Therapy for Previously Untreated Severe Aplastic Anemia
Ann Intern Med,
October 2, 2001;
135(7):
477 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kojima, S. Hibi, Y. Kosaka, M. Yamamoto, M. Tsuchida, H. Mugishima, K. Sugita, H. Yabe, A. Ohara, and I. Tsukimoto
Immunosuppressive therapy using antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia
Blood,
September 15, 2000;
96(6):
2049 - 2054.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bacigalupo, B. Bruno, P. Saracco, E. Di Bona, A. Locasciulli, F. Locatelli, A. Gabbas, C. Dufour, W. Arcese, G. Testi, et al.
Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients
Blood,
March 15, 2000;
95(6):
1931 - 1934.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tichelli, G. Socie, M. Henry-Amar, J. Marsh, J. Passweg, H. Schrezenmeier, S. McCann, J. Hows, P. Ljungman, P. Marin, et al.
Effectiveness of Immunosuppressive Therapy in Older Patients with Aplastic Anemia
Ann Intern Med,
February 2, 1999;
130(3):
193 - 201.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L A Pitcher, I M Hann, J P M Evans, P Veys, J M Chessells, and D K H Webb
Improved prognosis for acquired aplastic anaemia
Arch. Dis. Child.,
February 1, 1999;
80(2):
158 - 162.
[Abstract]
[Full Text]
|
|
|
|
|
